JPMorgan analyst Cory Kasimov reiterated his Overweight rating and $83 price target on Sage Therapeutics (NASDAQ: SAGE) saying they like ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE